Abstract
In order to define an enantioselective nuclear magnetic resonance (NMR) method for the antiasthmatic drug montelukast, a series of nine easily available products were evaluated as NMR chiral solvating agents (CSAs): D-dibenzoyltartaric acid, D-ditoluoyltartaric acid, (+)-camphorsulfonic acid, (S)-BINOL, (S)-3,3'-diphenyl-2,2'-binaphthyl-1,1'-diol, (R)-3,3''-di-9-anthracenyl-1,1''-bi-2-naphthol, (R)-3,3''-di-9-phenanthrenyl-1,1''-bi-2-naphthol, Pirkle's alcohol, and (-)-cinchonidine. It was proved that most of the studied agents constitute diastereomeric complexes with both drug enantiomers in CD2 Cl2 or CDCl3 solutions, thus permitting the direct (1)H NMR detection of the unwanted S-enantiomer, even at levels of 0.75%. (-)-Cinchonidine was found to be the more convenient CSA in terms of NMR enantiodiscrimination power and ease of experimental requirements. The final method was validated and applied to the fast monitoring of the optical purity of montelukast "in-process" samples, circumventing the need for tedious and slower analytical procedures like enantioselective chromatography or capillary electrophoresis. In addition, a method for the enantiopurity control of the commercial drug (montelukast sodium salt) was also established using (S)-BINOL as NMR CSA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
